Biogroup-LCD
Biogroup-LCD operates France's largest network of 900+ independent medical biology laboratories across 21+ regional divisions, serving 20,000+ patients daily with routine and specialty testing including fertility, genetics, COVID-19 screening, and preventive health, with international presence across Belgium, Luxembourg, UK, Spain, and Portugal.
- Company typePrivate
- Founded1998
- HeadquartersSaint-ouen, France
- Headcount10,001+
- GTM typeB2C
- OfferingServices
What Biogroup-LCD does
Biogroup-LCD is a France-headquartered private medical biology laboratory group operating the country's largest network of independent medical analysis laboratories, comprising 900+ locations organized into 21+ regional divisions (Biogroup Lorraine, Bretagne, Côte d'Azur, Île-de-France, Rhône Alpes, Provence, Alsace, Atlantique Centre, and others) and serving more than 20,000 patients daily with over 2,000 routine test types. The company has expanded internationally into Belgium, Luxembourg, the United Kingdom, and the Iberian Peninsula (Spain and Portugal) through the 2021 integration of Cerba Internacional and Analiza, employing 10,000+ people under founder-CEO Stephane Eimer. Its service portfolio spans routine clinical pathology, COVID-19 screening (RT-PCR, antigen, serology), assisted reproduction (Biogroup Fertilité with IVF, ICSI, insemination, and fertility preservation using Embryoscope, RI Witness, Zymot, and Embryoglue technologies), genetic testing, and prescription-free preventive health screenings (Bilans de Santé Sans Ordonnance).
The technical platform combines physical laboratory operations with digital patient infrastructure including the Mon Espace Biogroup portal (launched 2025) for online appointment pre-registration, secure result delivery, and PDF access, alongside integrations with MSSanté, HPRIM, and Apicrypt secure messaging for healthcare professional communications. A research infrastructure comprising a declared Biobank (DC-2020-4014 and AC-2023-5435), a Data Institute with epidemiological and predictive-modeling capabilities, and a CRO arm is supported by partnerships with CNRS research units, France Tissue Bank, Agoria Santé, and the national SNDS health data system. The company is actively evaluating AI capabilities including Deepia's Intelligent Analysis device for biological report interpretation and USENSE's DM-DIV JIMINI urinary diagnostic device.
Revenue is generated primarily through regulated tariffs billed to the French national health insurance system (Assurance Maladie) under the Nomenclature de Biologie Médicale for prescription-driven tests, with supplementary streams from out-of-pocket preventive screenings (Bilans sans ordonnance), partially-covered fertility procedures, postal result delivery surcharges (€2 per result), and home-visit fees. The GTM motion is direct-to-consumer for walk-in and pre-booked laboratory visits, and direct-to-professional for healthcare prescribers. In May 2026, Biogroup issued EUR 258.5 million in bonds at a 7.75% coupon maturing August 2031, with stabilization arranged by BNP Paribas, HSBC, JPMorgan, Citigroup, CACIB, NATIXIS, Deutsche Bank, and Goldman Sachs, signaling capital availability for continued consolidation and growth.
Biogroup-LCD firmographics
Firmographics- Name
- Biogroup-LCD
- Legal name
- Biogroup-LCD
- Website
- https://biogroup.fr
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 10,001+ employees
- Short description
- Biogroup-LCD operates France's largest network of 900+ independent medical biology laboratories across 21+ regional divisions, serving 20,000+ patients daily with routine and specialty testing including fertility, genetics, COVID-19 screening, and preventive health, with international presence across Belgium, Luxembourg, UK, Spain, and Portugal.
- Ownership category
- akta.pro rank
Biogroup-LCD industry classification
Industry- Product category
- Medical Biology Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)Clinical Research & Trial Central LaboratoriesMicrobiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)Specimen Referral, Transport & Chain-of-Custody Coordination NetworksHealthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing NetworksOccupational Health & Employer Testing Laboratories
Keywords
Where Biogroup-LCD is headquartered
LocationHeadquarters
- HQ city
- Saint-ouen
- HQ country
- France
- HQ region
- Europe
Offices15 records
Markets served
Biogroup-LCD business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Medical biology analysis services (Sécurité sociale / Assurance Maladie): Revenue is generated from clinical pathology tests performed at laboratories, billed to the French national health insurance system (Sécurité sociale/Assurance Maladie) at regulated tariffs (Nomenclature de Biologie Médicale). Additional co-payments or non-reimbursed services are billed to patients or supplementary health insurers (mutuelles). Standard blood tests, genetic analyses, fertility procedures, and other medical biology examinations are covered under this model.
- Out-of-pocket health screenings (Bilans sans ordonnance): Preventive health check-ups performed without a doctor's prescription are paid directly by patients (non-reimbursed by Assurance Maladie). These include health assessments for men, women, metabolic, cardiovascular, thyroid, diabetes, menopause, renal function, and STI/HIV screening. Mutuelle reimbursement may apply.
- Assisted Reproduction (PMA/AMP) procedures: Fertility treatments including IVF, ICSI, intrauterine insemination, fertility preservation, and sperm analysis are partially covered by Assurance Maladie up to age limits. Any non-covered or additional services are paid by patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Per service | Standard regulated laboratory tests — covered by Assurance Maladie with valid prescription |
| One time/ perpetual license | Pay-as-you-go | Preventive health screenings without prescription (Bilans sans ordonnance) — patient pays out-of-pocket |
| Unit Pricing | Per service | Result delivery by post — 2€ per result |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Biogroup-LCD product offering
Product offeringCore offering
Biogroup-LCD operates a network of 900+ independent medical biology laboratories (SEL/SELAS) across France and parts of Europe, performing routine and specialized clinical pathology analyses. It provides blood/urine testing, genetics, assisted reproduction (PMA/AMP/IVF), COVID-19 and infectious disease testing, and preventive health screenings, with digital results delivery and appointment booking.
Product overview
Biogroup-LCD operates a unified medical biology laboratory network comprising over 900 laboratory locations across France, organized into regional entities including Biogroup Lorraine, Biogroup Côte d'Azur, Biogroup Alpes, Biogroup Bretagne, Biogroup Provence, Biogroup Rhône-Alpes, Biogroup Maine Anjou, Biogroup Lorraine, Biogroup Centre Val de Loire, Biogroup Atlantique Centre, Biogroup Corse, Biogroup Bourgogne Franche-Comté, Biogroup Loire Ardèche, Biogroup Nord, Biogroup Oise, CAB (Biogroup-CAB), EIMER, and others. The core offering consists of clinical biology analysis services including routine testing, specialized diagnostics, Covid-19 testing, fertility services (Biogroup Fertilité), genetic testing, and preventive health checkups without prescription (Bilans de Santé Sans Ordonnance). Digital services include the Mon Espace Biogroup patient portal, online appointment scheduling, secure result transmission via MSSanté/HPRIM/Apicrypt, and a professional portal for healthcare providers. Research capabilities include a biobank, Data Institute for epidemiological studies, and contract research organization (CRO) services for external partners. The network expanded internationally to the Iberian Peninsula (Spain/Portugal) via integration of Cerba Internacional and Analiza.
Differentiator
Problem solved
Functional benefit
Brands
- Biogroup Fertilité: Specialized fertility and reproductive biology division offering IVF, ICSI, artificial insemination, fertility preservation, and fertility assessments
- Biogroup Genetics
- Biogroup COVID-19 Testing
Products and services
- Biogroup Medical Biology Laboratories Network of over 900 medical analysis laboratories across France providing clinical biology testing including routine blood tests, specialized diagnostics, and sample collection for patients and healthcare professionals.
- Biogroup Fertilité (Fertility Services) Assisted reproductive technology services including IVF, ICSI, artificial insemination, fertility preservation, and fertility assessments for women and men, with standardized protocols across dedicated centers.
- COVID-19 Testing Services COVID-19 diagnostic services including RT-PCR (nasopharyngeal and salivary), rapid antigenic tests, and serological antibody testing, with variant detection on positive samples.
- Genetic Testing Services Post-natal genetic testing including thrombophilia risk assessment, iron overload (hemochromatosis) testing, HLA-B27 susceptibility testing, and infertility-related genetic screening.
- Bilans de Santé Sans Ordonnance (Preventive Health Check-ups) Preventive health checkup packages available without a prescription, including men's health, women's health, kidney, metabolic, cardiovascular, thyroid, diabetes, and STI/HIV screening, paid out-of-pocket.
- Mon Espace Biogroup (Patient Portal) Secure patient portal providing online access to test results, secure PDF report downloads, online payment of remaining patient costs, and access to historical examination results.
- Online Appointment Scheduling & Pre-Registration Digital platform enabling patients to find laboratories, schedule appointments, and complete pre-registration online to reduce wait times and streamline visits.
- Biogroup Contract Research Organization (CRO) Contract research services enabling external pharmaceutical, biotech, and academic partners to conduct clinical validation studies using Biogroup's laboratory network and patient populations.
- Biogroup Biobank Declared biobank (DC-2020-4014, AC-2023-5435) enabling reuse of biological samples and associated medical data for scientific research projects under regulatory compliance.
- Professional Portal & Catalogue des Examens Online portal for healthcare professionals providing access to patient results, regional examination catalogs, practical documents, scientific bibliography, and newsletters.
Quantifiable outcome
- COVID-19 RT-PCR test false negative rate below 10% when pre-analytical requirements are met
- +1 more outcomes
Companies that use Biogroup-LCD
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Biogroup-LCD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability6 records
Feature11 records
Biogroup-LCD partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- France Tissue BankminorBiogroup collaborates with France Tissue Bank, an entity operating a health data repository. Biogroup contributes pseudonymized patient data to this data warehouse for specific, CNIL-authorized research purposes. The collaboration enables enrichment of health data for research while maintaining patient confidentiality.
- Agoria SantéminorBiogroup collaborates with Agoria Santé, a health data repository operator. Biogroup contributes data to this health data warehouse for research purposes under CNIL authorization. The partnership supports epidemiological studies and health outcomes research.
- Cerba InternacionalcoreBiogroup is expanding into the Iberian Peninsula through the integration of Cerba Internacional (Spain/Portugal). This acquisition/integration represents a major international expansion of Biogroup's laboratory network into Southern Europe.
- AnalizacoreBiogroup is expanding into the Iberian Peninsula by integrating Analiza alongside Cerba Internacional. Together, these acquisitions establish Biogroup's presence in Spain and Portugal.
- Bio-SantiscoreBiogroup expanded its presence in the Provence-Alpes-Côte d'Azur region by acquiring Bio-Santis, strengthening its laboratory network in a region where it was previously less represented.
- LabexaminorBiogroup was in discussions to acquire Labexa to strengthen its Provence-Alpes-Côte d'Azur network, with simultaneous negotiation underway for the potential resale of Labexa to Cerba (with a decision expected soon).
- CNAM / SNDS (Caisse Nationale de l'Assurance Maladie / Système National des Données de Santé)minorBiogroup enriches its patient data with information from the French national health data system (SNDS) including hospitalization data (PMSI), outpatient care reimbursement data (SNIIRAM), and medical causes of death data (BCMD), enabling comprehensive epidemiological research within regulatory frameworks.
- CNRS (various UMR units)minorBiogroup collaborates with CNRS research units (UMR 7241, UMR 7618, UMR 1678) on sharing epidemiological data for SARS-CoV-2 variant characterization and other research projects. Studies are conducted using pseudonymized patient data for public health research purposes.
- CNR PasteurminorBiogroup participates in the RELAB project (Surveillance of epidemiology of community respiratory viral infections) alongside CERBA, CERBALLIANCE, HCL (Hospices Civils de Lyon), and CNR Pasteur, forming a national laboratory surveillance network.
- CERBAminorBiogroup participates in the RELAB national laboratory surveillance network alongside CERBA, CERBALLIANCE, HCL, and CNR Pasteur. Additionally, discussions were held regarding the potential resale of Labexa to Cerba, with a decision expected at the time of reporting.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Biogroup-LCD competitors and assessment
Company assessmentDirect peers
- Inovie: Major French medical biology network (SEL/SELAS) providing routine and specialty diagnostics. Closest direct competitor in France, operating the same regional-roll-up model with overlapping prescribers and patient demographics.
- Synlab: Pan-European leader in medical diagnostic laboratory services with a comparable multi-country network and routine + specialty testing portfolio. Direct competitor for cross-border M&A targets and serves the same physician/patient base as Biogroup.
- Lifebrain: European clinical laboratory network with strong presence in Italy and other markets, offering routine and specialty diagnostics. Comparable multi-site network operator with similar GTM to physicians and patients.
- Cerba Healthcare: French-headquartered specialty clinical laboratory network offering routine biology, specialty testing, and central lab services. Operates in overlapping geographies and competes for the same regional laboratory acquisitions.
- amedes: Germany-headquartered medical diagnostics network providing clinical chemistry, genetics, and specialty laboratory services across Europe. Comparable scale and multi-site operating model to Biogroup.
- Unilabs: European clinical diagnostics and laboratory services group with presence in France, Iberia, and several other markets. Directly comparable network model, test menu, and physician-customer base.
Broad incumbents
- Quest Diagnostics: Large US-headquartered clinical laboratory operator with growing international presence. Comparable routine and specialty test menu and direct-to-consumer / physician service model.
- Eurofins Scientific: Global leader in bioanalytical testing across clinical, food, environmental, and pharmaceutical segments. Overlaps with Biogroup in clinical diagnostics and central lab services but operates a much broader testing portfolio.
- Sonic Healthcare: Global medical diagnostics operator with laboratory networks across Europe, Australia, and the US. Broad incumbent serving similar physician and hospital customers with routine and specialty testing.
- Labcorp: Global clinical laboratory and diagnostics business with routine, specialty, and clinical trial services. Broad incumbent with overlapping product capabilities and customer base to Biogroup.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Biogroup-LCD social profiles
Digital presenceBiogroup-LCD compliance and trust
Trust signalCompliance4 records
Biogroup-LCD financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biogroup-LCD leadership team
Management profileNumber of profiles
Profiles1 record
Biogroup-LCD subsidiaries and ownership
Company hierarchySubsidiaries25 records
Biogroup-LCD funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biogroup-LCD M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biogroup-LCD
What does Biogroup-LCD do?
Biogroup-LCD operates a network of 900+ independent medical biology laboratories (SEL/SELAS) across France and parts of Europe, performing routine and specialized clinical pathology analyses. It provides blood/urine testing, genetics, assisted reproduction (PMA/AMP/IVF), COVID-19 and infectious disease testing, and preventive health screenings, with digital results delivery and appointment booking.
When was Biogroup-LCD founded?
Biogroup-LCD was founded in 1998. It employs 10,001+ people.
Where is Biogroup-LCD based?
Biogroup-LCD is headquartered in Saint-ouen, France, in the Europe region.
How does Biogroup-LCD make money?
Three revenue lines are on record. Medical biology analysis services (Sécurité sociale / Assurance Maladie) is the primary driver. The others are out-of-pocket health screenings (Bilans sans ordonnance) and assisted Reproduction (PMA/AMP) procedures.
Who are Biogroup-LCD's main competitors?
Direct peers on record are Inovie, Synlab, Lifebrain, Cerba Healthcare, amedes and Unilabs. Broad incumbents are Quest Diagnostics, Eurofins Scientific, Sonic Healthcare and Labcorp.
Does Biogroup-LCD have an API?
No public API is recorded for Biogroup-LCD.
What industry is Biogroup-LCD in?
Biogroup-LCD's product category is Medical Biology Laboratory Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 621511 and its SIC code is 8071.